3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
6
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
34
Leukemia
7
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Hematologic Neoplasms
4
Recurrence
3
Neoplasms
2
Thrombocytopenia
1
Sarcoma, Myeloid
1
Sarcoma, Kaposi
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Leukemia, Myeloid
1
Immunoproliferative Disorders
1
HIV Infections
1
Disease
1
Congenital Abnormalities
1
Acquired Immunodeficiency Syndrome
1
Interventions
blinatumomab
5
midostaurin
2
Azacitidine
2
venetoclax
1
tisagenlecleucel
1
siremadlin
1
sabatolimab
1
pulrodemstat besilate
1
posaconazole
1
fludarabine phosphate
1
fludarabine
1
Zoledronic Acid
1
Vitamin D
1
N,N-dicyclohexyl-isoborneol-10-sulfonamide
1
Midazolam
1
Idarubicin
1
Drug Therapy
1
Daunorubicin
1
Cytarabine
1
Cyclophosphamide
1
Calcium
1
CD3 Complex
1
Anthracyclines
1
AP 1903 reagent
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasm, Residual
×
Daunorubicin
×
Clear all
NCT03760445
2020-01-09
HDM201 Added to CT in R/R or Newly Diagnosed AML
Novartis
Phase 1/2
Withdrawn